Stocks and Investing
Stocks and Investing
Fri, May 28, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
David Lebowitz Maintained (ASND) at Buy with Increased Target to $201 on, May 28th, 2021
David Lebowitz of Morgan Stanley, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $199 to $201 on, May 28th, 2021.
David has made no other calls on ASND in the last 4 months.
There are 2 other peers that have a rating on ASND. Out of the 2 peers that are also analyzing ASND, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Tuesday, March 30th, 2021
This is the rating of the analyst that currently disagrees with David
- Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $190 on, Friday, March 12th, 2021
Contributing Sources